Analysis of CDKN1A polymorphisms:: markers of cancer susceptibility?

被引:17
作者
Rodrigues, FCC
Kawasaki-Oyama, RS
Fo, JFG
Ukuyama, ÉE
Antonio, JR
Bozola, AR
Romeiro, JG
Rahal, P
Tajara, EH [1 ]
机构
[1] Univ Estadual Paulista, Dept Biol, Sao Carlos Do Rio Preto, SP, Brazil
[2] Fac Med Marilia, Hemoctr, Sao Paulo, Brazil
[3] Hosp Arnaldo Vieira De Carvalho, Sao Paulo, Brazil
[4] Fac Med, Serv Dermatol, Sao Carlos Do Rio Preto, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1016/S0165-4608(02)00839-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CDKN1A (TP21)(2) gene encodes a 21-kD protein that is a critical downstream mediator of wild-type TP53 and an important regulator of the cell cycle. Failure in the function of this gene would be expected to result in abnormal cell proliferation and transformation. Tumor-associated mutations of the coding region of the TP21 are rare. On the other hand, some TP21 polymorphisms have been identified and characterized by single base substitutions. In the present study, we investigated the potential role of TP21 gene polymorphisms in skin, head, and neck tumorigenesis. A total of 261 samples were examined by polymerase chain reaction single-strand conformational analysis, and one mutation at codon 31 and four polymorphisms in exons 2 (codon 55) and 3 [nucleotide (nt)590] and in promoter region (nt2298) were identified. In conclusion, this investigation confirmed the rarity of mutations in this gene, arguing against a role for TP21 mutations in skin, head, and neck cancers. Also, our results show significant differences in nt2298 allele frequencies between normal individuals and skin malignant tumors (P < 0.05). The results suggest that this polymorphism affects TP21 transactivator binding and may be important during the pathogenesis of skin cancer. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:92 / 98
页数:7
相关论文
共 37 条
[1]  
BAE IS, 1995, CANCER RES, V55, P2387
[2]   Novel polymorphism in p21waf1/cip1 cyclin dependent kinase inhibitor gene:: association with human esophageal cancer [J].
Bahl, R ;
Arora, S ;
Nath, N ;
Mathur, M ;
Shukla, NK ;
Ralhan, R .
ONCOGENE, 2000, 19 (03) :323-328
[3]   The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups [J].
Birgander, R ;
Sjalander, A ;
Saha, N ;
Spitsyn, V ;
Beckman, L ;
Beckman, G .
HUMAN HEREDITY, 1996, 46 (03) :148-154
[4]   p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo [J].
Cardinali, M ;
Jakus, J ;
Shah, S ;
Ensley, JF ;
Robbins, KC ;
Yeudall, WA .
ORAL ONCOLOGY, 1998, 34 (03) :211-218
[5]  
CHEDID M, 1994, ONCOGENE, V9, P3021
[6]  
CHEN YQ, 1995, CANCER RES, V55, P4536
[7]   Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1 [J].
Chin, YE ;
Kitagawa, M ;
Su, WCS ;
You, ZH ;
Iwamoto, Y ;
Fu, XY .
SCIENCE, 1996, 272 (5262) :719-722
[8]   RB regulates transcription of the p21/WAF1/CIP1 gene [J].
Decesse, JT ;
Medjkane, S ;
Datto, MB ;
Crémisi, CE .
ONCOGENE, 2001, 20 (08) :962-971
[9]   MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL [J].
DENG, CX ;
ZHANG, PM ;
HARPER, JW ;
ELLEDGE, SJ ;
LEDER, P .
CELL, 1995, 82 (04) :675-684
[10]  
ELDEIRY WS, 1994, CANCER RES, V54, P1169